TheTechno Optimist.

xT CDx genomic profilingTempus AI—FDA approves tumour-only use of Tempus's 648-gene xT CDx testxT CDx genomic profilingTempus AI—Tempus agrees to buy Personalis for USD 16.25 a share (about USD 1.5B) to add tumour-informed recurrence testingTempus AI—Tempus Q2 2026 revenue rises 22% to USD 382.5M; full-year guidance about USD 1.6BTempus AI—Tempus reports 2025 revenue of about USD 1.27B, up 83%, and guides to its first positive adjusted EBITDA year

Tempus AI

Cancer DNA tests, clinical data, AI models

USpublicest. 2015Checked 11 Oct

The brief

Analyst view
  • 2025 revenue was about USD 1.27B (+83%, helped by buying Ambry Genetics); 2026 guidance USD 1.595-1.605B.
  • FDA approved its 648-gene xT CDx test for tumour-only use in May 2026, on top of the 2023 tumour-plus-normal approval.
  • Agreed in July 2026 to buy Personalis, maker of a cancer-recurrence blood test, for about USD 1.5B.

Technical approach

As reported
Tests

Sequence the tumour, report the options

Tissue and blood tests read hundreds of cancer genes and flag mutations that match approved drugs or open trials for that patient.

Data

Every test feeds a data library

De-identified test results are joined with treatment and outcome records, then licensed to drug makers for research and trial design.

AI

Models trained on that library

Tempus builds AI tools, such as Paige Predict for pathology slides and an oncology foundation model built with AstraZeneca and Pathos.

Monitoring

From diagnosis to relapse

Hereditary tests (Ambry) and blood tests for leftover cancer (Personalis's NeXT Personal) extend coverage before and after treatment.

Primer